OPKO Health Inc (OPK)

10.40
NASDAQ : Health Care
Prev Close 10.31
Day Low/High 10.23 / 10.49
52 Wk Low/High 7.12 / 11.85
Avg Volume 3.48M
Exchange NASDAQ
Shares Outstanding 557.53M
Market Cap 5.75B
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Opko Health Has 3 Very Attractive Charts

Opko Health Has 3 Very Attractive Charts

But it now or buy it when it's higher.

Opko Healthcare's Phillip Frost Is a Major Microcap Investor

Opko Healthcare's Phillip Frost Is a Major Microcap Investor

Opko Healthcare's CEO is chairman of an investment bank and number 134 on the Forbes 400 richest people in the world.

'Mad Money' Lightning Round: I'm Faithful to Opko Health's CEO

'Mad Money' Lightning Round: I'm Faithful to Opko Health's CEO

Cramer is avoiding TPC Composites and is lukewarm on Kinder Morgan.

Jim Cramer's 'Mad Money' Recap: Don't Play the Short-Term Market Game

Jim Cramer's 'Mad Money' Recap: Don't Play the Short-Term Market Game

Consistency and discipline are two values this market has sorely lacked in 2016, Cramer says.

OPKO Health Appoints Dr. Benjamin Solomon As Managing Director Of GeneDx

OPKO Health Appoints Dr. Benjamin Solomon As Managing Director Of GeneDx

OPKO Health, Inc. (NASDAQ:OPK), announces the appointment of Benjamin D.

OPKO Health To Present At The Ladenburg Thalmann 2016 Healthcare Conference

OPKO Health To Present At The Ladenburg Thalmann 2016 Healthcare Conference

OPKO Health, Inc. (NASDAQ:OPK) today announced that senior management will present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27th, 2016 at 10:30 AM (ET).

Look for Test of Key Index Again

Besides testing the S&P 500's 2100 level, we're also likely to see volume pick up as we head toward Friday's triple-witching expiration finale.

OPKO Health Appoints Jane Pine Wood As Chief Legal And Compliance Officer Of BioReference Laboratories

OPKO Health Appoints Jane Pine Wood As Chief Legal And Compliance Officer Of BioReference Laboratories

OPKO Health, Inc. (Nasdaq: OPK) announces the appointment of Jane Pine Wood, Esq.

OPKO To Present Long-acting Human Growth Hormone (hGH-CTP) Phase 2 Pediatric Growth Hormone Deficiency Data At The 55th Annual Meeting Of The European Society For Paediatric Endocrinology

OPKO To Present Long-acting Human Growth Hormone (hGH-CTP) Phase 2 Pediatric Growth Hormone Deficiency Data At The 55th Annual Meeting Of The European Society For Paediatric Endocrinology

OPKO Health, Inc. (NASDAQ:OPK) will present abstracts at the 55 th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) to be held in Paris, France on September 10-12, 2016.

OPKO Health To Participate In Upcoming September Conferences

OPKO Health To Participate In Upcoming September Conferences

OPKO Health, Inc. (Nasdaq: OPK), today announced that senior management will participate in the 11 th Annual Wells Fargo Securities Healthcare Conference taking place September 7-8, 2016 in Boston and the 9 th Annual...

OPKO Health Completes Acquisition Of Transition Therapeutics

OPKO Health Completes Acquisition Of Transition Therapeutics

OPKO Health, Inc. (NASDAQ: OPK), announces that it has completed its previously announced acquisition of Transition Therapeutics, Inc.

'Mad Money' Lightning Round: I Am Committed to Opko Health

'Mad Money' Lightning Round: I Am Committed to Opko Health

Cramer says SolarCity is too hard for him and he's losing patience with Cigna.

Jim Cramer's 'Mad Money' Recap: These Are the Sectors to Buy Now

Jim Cramer's 'Mad Money' Recap: These Are the Sectors to Buy Now

With interest rate hikes this year a distinct possibility, the big money managers are springing into action, Cramer says. Here's what to buy.

Transition Therapeutics Shareholders Approve Acquisition By OPKO Health

Transition Therapeutics Shareholders Approve Acquisition By OPKO Health

OPKO Health, Inc. (Nasdaq: OPK), announces that at a Special Shareholder Meeting held on August 25, 2016 shareholders of Transition Therapeutics, Inc.

OPKO Health Responds To Law Firm Notice Of Investigation

OPKO Health Responds To Law Firm Notice Of Investigation

OPKO Health, Inc. (NYSE:OPK), is aware of a press release by Purcell Julie & Lefkowitz, LLP, a class action litigation firm, that it is investigating the Company for an alleged potential breach of fiduciary duty claim...

Opko Health (OPK) Stock Higher After Q2 Earnings Beat

Opko Health (OPK) Stock Higher After Q2 Earnings Beat

Opko Health (OPK) posted earnings and revenue that topped analysts' estimates for the 2016 second quarter following Monday's market close.

OPKO Health Reports Improved Financial And Operating Results

OPKO Health Reports Improved Financial And Operating Results

OPKO Health, Inc. (NYSE:OPK), reports financial and operating results for the three and six months ended June 30, 2016.

'Mad Money' Lightning Round: I'm Still With Opko Health

'Mad Money' Lightning Round: I'm Still With Opko Health

Cramer wants you to stick with Abbvie and says Cepheid is working.

Jim Cramer's 'Mad Money' Recap: Four Winning Themes, Four to Avoid

Jim Cramer's 'Mad Money' Recap: Four Winning Themes, Four to Avoid

Cramer has seen enough in this earnings season to come to some conclusions on what's working and what isn't.

OPKO To Announce Second Quarter Operating And Financial Results On August 8, 2016

OPKO To Announce Second Quarter Operating And Financial Results On August 8, 2016

OPKO Health, Inc. (NASDAQ:OPK) will release operating and financial results for the three and six months ended June 30, 2016, after the close of the U.

Opko Is a Buying Opportunity After FDA's Approval of Kidney Drug

Opko Is a Buying Opportunity After FDA's Approval of Kidney Drug

Banking on its Rayaldee treatment, this once-quiet pharmaceutical company has stepped up its investor profile with its first analyst day and a recent move to Nasdaq.

OPKO Health To Acquire Transition Therapeutics

OPKO Health To Acquire Transition Therapeutics

OPKO Health, Inc. (NASDAQ:OPK) and Transition Therapeutics Inc.